Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA ASPIRE-T
- Development stage
- Preclinical
- Lead developer
- TCRCure Biotech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Parenteral
01
Overview
BCMA ASPIRE-T is an investigational, next-generation chimeric antigen receptor T-cell (CAR-T) therapy being developed by TCRCure Biotech (TCRCure Biopharma) for the treatment of multiple myeloma. Utilizing TCRCure's proprietary ASPIRE-T platform, the therapy is designed to redirect the TCR/CD3 complex to overcome the limitations of conventional CAR-T and TCR-T therapies, aiming to deliver robust, sustained, and safer immune responses. The candidate targets B-cell maturation antigen (BCMA), a cell surface receptor highly expressed on malignant plasma cells in multiple myeloma, and is currently in preclinical development.
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on BCMA ASPIRE-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA ASPIRE-T.